Blog Archives

Martine Barkats and Maria Grazia Biferi awarded the Avi Kremer ALS Treatment Prize from Prize4Life for their gene therapy approach

Martine Barkats and Maria Grazia Biferi have received the Avi Kremer ALS Treatment Prize from Prize4Life, which is committed to the fight against Amyotrophic Lateral Sclerosis (ALS*) and awards $1 million to the winners. Within the Myology Research Centre (MRC) of the Institute of Myology, the team “CNS Gene Transfer & Biotherapy of Motor Neuron … [Read more]

Novel synaptobrevin-1 mutation causes fatal congenital myasthenic syndrome

  In this study, clinical electrophysiology studies, exome and Sanger sequencing were used to identify the molecular basis and elucidate the pathogenesis of a fatal congenital myasthenic syndrome. Clinical electrophysiology studies of the patient revealed several-fold potentiation of the evoked muscle action potential by high frequency nerve stimulation pointing to a presynaptic defect. Exome sequencing … [Read more]

CRISPR/Cas9 technology: therapeutic implications for patients with DM1

Myotonic dystrophy type 1 (DM1) is caused by (CTG⋅CAG)n-repeat expansion within the DMPK gene and thought to be mediated by a toxic RNA gain of function. Current attempts to develop therapy for this disease mainly aim at destroying or blocking abnormal properties of mutant DMPK (CUG)n RNA. Here, the authors explored a DNA-directed strategy and … [Read more]

HSPB1 and HSPB8 mutations are a major cause of inherited motor axonal neuropathy

  This study describes the phenotypic spectrum of distal hereditary motor neuropathy caused by mutations in the small heat shock proteins HSPB1 and HSPB8 and investigate the functional consequences of newly discovered variants. Among 510 unrelated patients with distal motor neuropathy, the authors identified mutations in HSPB1 (28 index patients/510; 5.5%) and HSPB8 (4 index … [Read more]

The Letournel technique is an effective long-term solution in FSHMD dystrophy

The aim of this retrospective study was to evaluate long-term radio-clinical outcome in scapulothoracic fusion using the Letournel technique (where the fourth rib is passed through the wing of the scapula and cerclage wires are tightened to the two ribs below) for patients suffering from facioscapulohumeral muscular dystrophy (FSHMD. Mean improvement in range of motion … [Read more]

ACTN3 is a modifier of clinical phenotype in DMD

There is considerable inter-patient variability in disease onset and progression in Duchenne muscular dystrophy (DMD), which can confound the results of clinical trials. Here the authors show that a common null polymorphism (R577X) in ACTN3 results in significantly reduced muscle strength and a longer 10 m walk test time in young, ambulant patients with DMD; both … [Read more]

Functional trajectory of drisapersen-treated DMD patients compared to a matched natural history cohort

Duchenne muscular dystrophy is a rare genetic disorder with life-limiting pathology. Drisapersen induces exon 51 skipping, thereby producing a shorter but functional dystrophin protein. The longest available data are from an open-label extension study (PRO051-02) treating 12 boys with drisapersen (6 mg/kg/week subcutaneously). The median change (range) from baseline to week 177 in six-minute walking … [Read more]

Institute seminar – 13 March – Dada Pisconti Ph.D. (UK)

Of genes, sugars and proteins: a journey into the muscle stem cell niche Dada Pisconti Ph.D. (Department of Biochemistry,Centre for Glycobiology, Institute of Integrative Biology, University of Liverpool, UK) Monday 13 March 2017 – 12:00-13:00 Host : Fabien Le Grand Institute of Myology auditorium Hôpital de la Pitié-Salpêtrière Building Babinski Entrance 82 bd Vincent Auriol metro … [Read more]

Comprehensive pan-ethnic SMN1 copy-number and sequence variation

This study aimed to investigate pan-ethnic SMN1 copy-number and sequence variation by hybridization-based target enrichment coupled with massively parallel sequencing or next-generation sequencing (NGS). Ten single-nucleotide variants in SMN1 were detectable by NGS and confirmed by gene-specific amplicon-based sequencing. This comprehensive approach yielded SMA carrier detection rates of 90.3-95.0% in five ethnic groups studied. The … [Read more]

Endocytosis: major cellular mechanism perturbed in SMA

Homozygous SMN1 loss causes spinal muscular atrophy (SMA), the most common lethal genetic childhood motor neuron disease. SMN1 encodes SMN, a ubiquitous housekeeping protein, which makes the primarily motor neuron-specific phenotype rather unexpected. SMA-affected individuals harbor low SMN expression from one to six SMN2 copies, which is insufficient to functionally compensate for SMN1 loss. However, … [Read more]